Complete information in Russian

The main aim of treatment of opiate dependence is complete abstinence. However, opiate dependence treatment is an extremely difficult disease to treat.

Treatment of drug dependence is a difficult multi-aspect process, and this treatment does not always result in a stable remission.

In European Union substitution therapy (ST) is mainly used in treatment of opiate dependence.

For this purpose opiate receptor agonists (methadone therapy - MT, buprenorphine) are used. Substitution therapy has a number of drawbacks: Methadone related deaths, growth of methadone dependence, and misuse of buprenorphine which made a buprenorphine abuse and dependence a serious problem in Finland in particular.

Ultimate ST aim is to prepare a patient for a life without opiates.

The most effective method providing a stable abstinence is the treatment with opioid antagonists (OA). In the European Union currently available OA include only oral formulations.

The main problem of these medicinal forms is a poor compliance: Patients are not taking these medication as prescribed.

Long-acting medications is the best and easiest way to solve the problem of poor compliance.

At present there are no long-acting OA in the European pharmaceutical market.

In the Russian Federation treatment of opiate dependence with officially registered long-acting OA (Vivitrol, Prodetoxone) for 1-4 months are widely used because substitution therapy is legally prohibited.

NOVOERG offers highly professional, effective treatment of opiate dependence in Russia, St.-Petersburg.

NOVOERG provides gathering and supply of patients with the information necessary for treatment, renders service on patients transfer.

Novoerg proposal treatment in Russian